Claris Lifesciences Limited, is a BSE listed company, is a multi-business enterprise and the Holding Company of Claris Injectables - a wholly-owned subsidiary negotiating in Specialty Injectables business, collectively ‘Claris’; and Claris Otsuka - a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. Ltd. for Infusion business in India & Emerging Markets .
The morning of 29th August saw Claris Lifesciences share price trading at Rs. 260, fell sharply by 4%. The stock opened at Rs. 266.10 against its previous close at Rs. 271.75, according to BSE. The stock touched the day’s high and low at Rs. 267.65 and Rs. 251.80.
On a quarterly basis the Company’s consolidated revenues for the quarter ended 30th June 2016 have been seen at Rs 197.67 crores versus Rs 166.76 crores, an increase of 18.5 per cent
In other news, Claris Lifesciences informed that it’s wholly owned subsidiary; Claris Injectables Limited; had gone through an US FDA inspection; categorized as Prior Approval Inspection(PAI) scheduled from 16th August to 26th August; on the plant 1( Claron1) of its manufacturing facility located at Charcharvadi, Vasna. The company has been given five 483’s during the inspection; it is brewing with confidence to reply within 15 business days, with corrective and preventive actions to address the same.
The closest support level of Claris Lifesciences is seen at Rs. 250.65 while the closest resistance level stands at Rs. 290.25.
No comments:
Post a Comment